Elicio Therapeutics Inc.

NASDAQ: ELTX · Real-Time Price · USD
11.87
2.03 (20.63%)
At close: Aug 18, 2025, 10:39 AM

Elicio Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a 28.31M
Cost of Revenue
1.18M 1.17M 1.06M 1.23M
Gross Profit
-1.18M -1.17M -1.06M 27.08M
Operating Income
-44.99M -35.74M -23.73M -25.47M
Interest Income
777K 373K 64.83K 3.39K
Pretax Income
-51.9M -35.2M -28.21M -26.4M
Net Income
-51.9M -35.2M -28.21M -26.4M
Selling & General & Admin
11.33M 11.9M 5.63M 7.54M
Research & Development
33.66M 22.68M 18.1M 17.93M
Other Expenses
-1.18M n/a n/a n/a
Operating Expenses
43.81M 34.58M 23.73M 25.47M
Interest Expense
455K 1.06M 3.6M 876.44K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
44.99M 35.74M 23.73M 25.47M
Income Tax Expense
n/a n/a n/a 876.44K
Shares Outstanding (Basic)
12.2M 5.06M 3.1M 3.2M
Shares Outstanding (Diluted)
12.2M 5.06M 3.1M 3.2M
EPS (Basic)
-4.25 -6.96 -9.1 -19.32
EPS (Diluted)
-4.25 -6.96 -9.1 -19.32
EBITDA
-50.27M -32.97M -23.55M -51.92M
EBIT
-51.44M -34.14M -24.61M -52.73M
Depreciation & Amortization
1.18M 1.17M 1.06M 801K